Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.97 Insider Own1.20% Shs Outstand91.97M Perf Week-2.69%
Market Cap3.00B Forward P/E- EPS next Y-0.97 Insider Trans-14.53% Shs Float80.63M Perf Month-18.96%
Income-77.00M PEG- EPS next Q-0.45 Inst Own70.90% Short Float6.68% Perf Quarter-24.41%
Sales256.60M P/S11.67 EPS this Y13.60% Inst Trans-0.12% Short Ratio7.57 Perf Half Y-10.10%
Book/sh5.96 P/B5.46 EPS next Y11.00% ROA-8.90% Target Price62.71 Perf Year-38.30%
Cash/sh5.80 P/C5.61 EPS next 5Y- ROE-13.80% 52W Range22.65 - 55.63 Perf YTD-24.06%
Dividend- P/FCF- EPS past 5Y22.50% ROI-15.30% 52W High-41.46% Beta1.71
Dividend %- Quick Ratio6.80 Sales past 5Y13.30% Gross Margin99.60% 52W Low43.80% ATR3.24
Employees531 Current Ratio6.80 Sales Q/Q-92.60% Oper. Margin-34.80% RSI (14)46.35 Volatility7.80% 11.44%
OptionableYes Debt/Eq0.13 EPS Q/Q-560.10% Profit Margin-30.00% Rel Volume0.49 Prev Close34.04
ShortableYes LT Debt/Eq0.11 EarningsMar 02 AMC Payout- Avg Volume711.47K Price32.57
Recom1.90 SMA203.49% SMA50-15.58% SMA200-21.60% Volume349,586 Change-4.32%
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Mar-27-20 02:52PM  Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus Insider Monkey
Mar-24-20 04:23PM  Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +12.38%
Mar-04-20 07:07AM  Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results Simply Wall St. +6.21%
Mar-03-20 08:13PM  Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT Thomson Reuters StreetEvents -8.55%
05:50PM  After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push American City Business Journals
Mar-02-20 05:15PM  FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:01PM  FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-24-20 12:30PM  Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 07:00AM  FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-12-20 09:45AM  FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA Zacks
09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 05:00PM  FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease GlobeNewswire
08:00AM  FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-03-20 03:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
Jan-31-20 09:12AM  FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Jan-30-20 12:01AM  Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan PR Newswire
Jan-13-20 05:59PM  2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc (FGEN) Insider Monkey
Jan-06-20 06:03PM  Four months after CEO's death, biotech company names Lilly vet as leader American City Business Journals
07:00AM  FibroGen Names Enrique Conterno as Chief Executive Officer GlobeNewswire
Dec-24-19 08:55AM  Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock? Zacks
Dec-23-19 05:42PM  Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests American City Business Journals
07:00AM  FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease GlobeNewswire
Dec-17-19 06:45AM  Is FibroGen's (NASDAQ:FGEN) 136% Share Price Increase Well Justified? Simply Wall St.
Dec-06-19 10:03AM  Hedge Funds Have Never Been This Bullish On FibroGen Inc (FGEN) Insider Monkey
Dec-02-19 07:00AM  FibroGen Announces Roxadustat Inclusion in Chinas National Reimbursement Drug List GlobeNewswire
Nov-15-19 02:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE +5.75%
Nov-14-19 07:42PM  FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
05:24PM  Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-13-19 08:03PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
07:00PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
06:19PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
02:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
Nov-11-19 05:15PM  FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks -14.94%
05:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
04:01PM  FibroGen Reports Third Quarter 2019 Financial Results GlobeNewswire
09:21AM  FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks
Nov-08-19 02:10PM  FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease GlobeNewswire +9.61%
01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 04:39PM  FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease GlobeNewswire
Nov-06-19 10:41AM  Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss Zacks
10:36AM  Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
09:52AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN) ACCESSWIRE
08:52AM  Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks
Nov-05-19 10:18PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud PR Newswire +8.00%
05:24PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
11:17AM  Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance Zacks
10:42AM  Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
Nov-04-19 04:38PM  FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws GlobeNewswire -7.52%
07:00AM  FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 GlobeNewswire
Oct-31-19 06:53AM  5 Stocks With High Net Income Ratio to Grab Now Zacks
Oct-24-19 12:17PM  Is FibroGen Inc (FGEN) Going To Burn These Hedge Funds ? Insider Monkey
08:17AM  Does Market Volatility Impact FibroGen, Inc.'s (NASDAQ:FGEN) Share Price? Simply Wall St.
Oct-23-19 07:00AM  FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer GlobeNewswire
Oct-17-19 11:20AM  Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock Zacks
Oct-16-19 08:45AM  5 Stocks With High Net Income Ratio to Scoop Up Zacks
Oct-11-19 10:58AM  Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019 GlobeNewswire
Oct-07-19 05:57PM  FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine GlobeNewswire
06:41AM  UK and US scientists win Nobel Medicine Prize Financial Times
Oct-03-19 10:59AM  FibroGen Enters Oversold Territory Zacks
09:42AM  Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2% Zacks
Sep-30-19 08:00PM  FibroGen Receives One of China Pharmaceutical Industrys Highest Awards for Clinical Innovation for Roxadustat GlobeNewswire
07:00AM  FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-27-19 11:03AM  FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia Zacks
Sep-26-19 11:16AM  Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks
09:00AM  BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors Zacks
07:00AM  FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy GlobeNewswire
Sep-25-19 08:34AM  Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8% Zacks
Sep-23-19 01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
12:36PM  Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs Zacks
Sep-20-19 11:54AM  FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD Zacks
03:05AM  Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients GlobeNewswire
03:00AM  Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients PR Newswire
Sep-18-19 08:13AM  Is FibroGen, Inc.'s (NASDAQ:FGEN) 7.6% ROE Worse Than Average? Simply Wall St.
Sep-13-19 11:38AM  Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ Zacks
Sep-12-19 08:40AM  What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
07:08AM  5 Stocks with High Net Income Ratio to Grab Now Zacks
Sep-10-19 11:46AM  Theravance Announces Positive Early Data on JAK Inhibitor Zacks
04:56AM  Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised) Zacks
Sep-09-19 09:50AM  Endo International Files BLA for Label Expansion of Xiaflex Zacks
Sep-03-19 08:35AM  Radius (RDUS) Catches Eye: Stock Jumps 6.8% Zacks -6.72%
Aug-29-19 09:50AM  Ensign Group to Spin Off Home Health & Hospice Business Zacks
Aug-27-19 09:00AM  FibroGen (FGEN) Catches Eye: Stock Jumps 7.4% Zacks
Aug-26-19 07:33PM  FibroGen CEO Thomas Neff dies suddenly as company drives toward first FDA drug approval American City Business Journals +7.38%
08:30AM  Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive GlobeNewswire
Aug-23-19 06:15PM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares GuruFocus.com
Aug-22-19 06:08PM  AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China Zacks
07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
Aug-21-19 04:11PM  Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis GlobeNewswire
Aug-20-19 04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-19-19 05:55PM  Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4 Zacks
Aug-15-19 10:16PM  Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
01:15AM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares GuruFocus.com
Aug-14-19 09:51AM  Tilray (TLRY) Catches Eye: Stock Jumps 8.4% Zacks
Aug-13-19 09:44AM  FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Aug-09-19 11:07PM  FibroGen Inc (FGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:00PM  FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates Zacks
Aug-01-19 08:39PM  CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
07:24PM  FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
Jul-30-19 10:38AM  Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline Zacks
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEARNS THOMAS F JRDirectorMar 19Option Exercise2.9018,00052,200161,464Mar 23 05:37 PM
Chung ChristineSVP, China OperationsMar 19Option Exercise25.407,345186,563166,358Mar 19 07:55 PM
KEARNS THOMAS F JRDirectorMar 19Sale23.1718,000417,074143,464Mar 23 05:37 PM
Chung ChristineSVP, China OperationsMar 19Sale25.917,345190,282159,013Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Option Exercise25.4040010,160162,918Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Sale24.793,90596,799159,013Mar 19 07:55 PM
Yu K PeonyChief Medical OfficerMar 16Option Exercise19.393,75072,713166,541Mar 18 08:05 PM
Cotroneo PatSVP, Finance and CFOMar 16Sale26.369,239243,540236,466Mar 18 08:00 PM
Chung ChristineSVP, China OperationsFeb 12Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 12Sale45.985,625258,617132,644Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Sale44.485,625250,200132,644Feb 13 05:36 PM
Kurkijarvi KaleviDirectorFeb 10Option Exercise18.346,000110,04034,400Feb 12 09:52 PM
Kurkijarvi KaleviDirectorFeb 10Sale42.696,000256,14028,400Feb 12 09:52 PM
Chung ChristineSVP, China OperationsJan 07Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 07Sale42.765,625240,525132,644Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 06Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Kurkijarvi KaleviDirectorJan 06Option Exercise18.006,000108,00034,400Jan 08 09:14 PM
Chung ChristineSVP, China OperationsJan 06Sale42.985,625241,763132,644Jan 08 09:12 PM
Kurkijarvi KaleviDirectorJan 06Sale42.666,000255,96028,400Jan 08 09:14 PM
Cotroneo PatSVP, Finance and CFODec 20Option Exercise7.8156,254439,427310,042Dec 26 04:25 PM
Cotroneo PatSVP, Finance and CFODec 20Sale45.6759,4562,715,517250,586Dec 26 04:25 PM
Chung ChristineSVP, China OperationsDec 17Option Exercise25.405,625142,875138,269Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 17Sale46.985,625264,244132,644Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 16Option Exercise25.402,12053,848138,269Dec 18 08:33 PM
Yu K PeonyChief Medical OfficerDec 16Sale46.683,420159,646172,617Dec 17 08:38 PM
Chung ChristineSVP, China OperationsDec 16Sale47.085,625264,832132,644Dec 18 08:33 PM
Kurkijarvi KaleviDirectorDec 09Option Exercise18.006,000108,00034,400Dec 12 06:08 PM
Kurkijarvi KaleviDirectorDec 09Sale47.506,000285,00028,400Dec 12 06:08 PM
Yu K PeonyChief Medical OfficerDec 04Option Exercise17.464,15772,576179,397Dec 06 07:51 PM
Chung ChristineSVP, China OperationsNov 14Option Exercise21.845,625122,838145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 14Sale34.745,625195,440139,628Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Option Exercise19.395,625109,069145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Sale34.545,625194,288139,628Nov 15 06:07 PM
Cotroneo PatSVP, Finance and CFONov 08Option Exercise2.9012,50036,250256,932Nov 12 09:15 PM
Kurkijarvi KaleviDirectorNov 07Option Exercise9.786,00058,65034,400Nov 08 06:05 PM
Kurkijarvi KaleviDirectorNov 07Sale38.276,000229,62428,400Nov 08 06:05 PM
Chung ChristineSVP, China OperationsOct 09Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 09Sale36.585,625205,763139,628Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Sale36.785,625206,914139,628Oct 10 07:57 PM
Kurkijarvi KaleviDirectorOct 07Option Exercise9.786,00058,65034,400Oct 09 08:26 PM
Kurkijarvi KaleviDirectorOct 07Sale36.736,000220,38028,400Oct 09 08:26 PM
Chung ChristineSVP, China OperationsSep 20Option Exercise19.395,625109,069145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 20Sale39.875,625224,269139,628Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Option Exercise19.392,12041,107145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Sale40.455,625227,550139,628Sep 23 06:57 PM
Cotroneo PatSVP, Finance and CFOSep 17Sale41.383,201132,457244,432Sep 18 07:42 PM
Yu K PeonyChief Medical OfficerSep 16Sale40.923,419139,905175,240Sep 18 07:45 PM
Kurkijarvi KaleviDirectorSep 09Option Exercise5.956,00035,70034,400Sep 10 08:29 PM
Kurkijarvi KaleviDirectorSep 09Sale40.956,000245,72328,400Sep 10 08:29 PM
Chung ChristineSVP, China OperationsAug 23Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 23Sale42.515,625239,099151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Option Exercise2.906,83419,8192,345,012Aug 23 04:49 PM
Chung ChristineSVP, China OperationsAug 22Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 22Sale43.845,625246,583151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.771,41862,06644,238Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.8718,400807,1292,326,612Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise2.906,83419,8192,356,578Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.811,41863,54145,656Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.7918,400824,1362,338,178Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 13Option Exercise2.906,83419,8192,368,144Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.611,41864,68047,074Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.6518,400840,0062,349,744Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Option Exercise2.906,83419,8192,379,710Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.171,41864,05648,492Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.2418,400832,3292,361,310Aug 14 05:38 PM
Kurkijarvi KaleviDirectorAug 05Option Exercise3.506,00021,00034,400Aug 07 04:42 PM
Kurkijarvi KaleviDirectorAug 05Sale45.226,000271,32028,400Aug 07 04:42 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.906,83419,8192,391,276Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.9518,400863,8582,372,876Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.881,41866,47249,910Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.906,83419,8192,402,842Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.5418,400856,3362,384,442Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.571,41866,03651,328Jul 26 05:31 PM
Chung ChristineSVP, China OperationsJul 11Option Exercise28.215,625158,663157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Option Exercise2.906,83419,8192,414,408Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.091,41863,93852,746Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.1518,400830,8362,396,008Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 11Sale45.145,625253,915151,570Jul 12 04:23 PM
Chung ChristineSVP, China OperationsJul 10Option Exercise29.665,625166,838157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 10Option Exercise2.906,83419,8192,425,974Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.811,41863,54154,164Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.8018,400824,3002,407,574Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Sale44.795,625251,953151,570Jul 12 04:23 PM
Kurkijarvi KaleviDirectorJul 08Option Exercise3.506,00021,00034,400Jul 10 08:18 PM
Kurkijarvi KaleviDirectorJul 08Sale42.606,000255,57028,400Jul 10 08:18 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 28Sale45.002,873129,285109,199Jul 02 08:11 PM
Neff Thomas BChief Executive OfficerJun 20Option Exercise2.906,83419,8192,437,540Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.3918,400816,8202,419,140Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.321,41862,84055,582Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Option Exercise29.665,625166,838157,195Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Option Exercise2.906,83419,8192,449,106Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Sale44.025,625247,613151,570Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Sale44.0218,400809,9682,430,706Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 19Sale43.991,41862,37857,000Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 18Option Exercise29.662,12062,879157,195Jun 20 06:15 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 18Option Exercise14.5816,000233,200112,072Jun 20 06:19 PM
Cotroneo PatSVP, Finance and CFOJun 18Sale43.123,201138,027250,777Jun 20 06:18 PM
Chung ChristineSVP, China OperationsJun 18Sale44.085,625247,950151,570Jun 20 06:15 PM
open in yahoo | open in reuters | open in google